www.afirma.com Open in urlscan Pro
141.193.213.10  Public Scan

Form analysis
1 forms found in the DOM

POST" https://cloud.mail.veracyte.com/afirmawebform

<form action="https://cloud.mail.veracyte.com/afirmawebform" method="post&quot;" id="c-form">
  <div class="fc-element">
    <label>First name <span>*</span></label>
    <input type="text" name="fname" required="">
  </div>
  <div class="fc-element">
    <label>Last name <span>*</span></label>
    <input type="text" name="lname" required="">
  </div>
  <div class="fc-element">
    <label>Email <span>*</span></label>
    <input type="text" name="email" required="">
  </div>
  <div class="fc-element">
    <label>Institution <span>*</span></label>
    <input type="text" name="orgname" required="">
  </div>
  <div class="fc-element">
    <label>Zip code <span>*</span></label>
    <input type="text" name="zipcode" required="">
  </div>
  <div class="fc-checkboxes-group">
    <div class="fc-checkboxes-group-label">Which tests interest you (select all that apply) <span>*</span></div>
    <input type="checkbox" name="product" id="cb1" value="Afirma Genomic Sequencing Classifier">
    <label for="cb1">Afirma Genomic Sequencing Classifier</label>
    <input type="checkbox" name="product" id="cb2" value="Afirma Xpression Atlas">
    <label for="cb2">Afirma Xpression Atlas</label>
  </div>
  <div class="fc-checkboxes-group">
    <div class="fc-checkboxes-group-label">More about you <span>*</span></div>
    <input type="radio" name="specialty" id="spec1" value="Endocrinologist">
    <label for="spec1">Endocrinologist</label>
    <input type="radio" name="specialty" id="spec2" value="Endocrine surgeon">
    <label for="spec2">Endocrine surgeon</label>
    <input type="radio" name="specialty" id="spec3" value="Head and neck surgeon">
    <label for="spec3">Head and neck surgeon</label>
    <input type="radio" name="specialty" id="spec4" value="General surgeon">
    <label for="spec4">General surgeon</label>
    <input type="radio" name="specialty" id="spec5" value="Surgeon">
    <label for="spec5">Surgeon</label>
    <input type="radio" name="specialty" id="spec6" value="Radiologist">
    <label for="spec6">Radiologist</label>
    <input type="radio" name="specialty" id="spec7" value="Pathologist">
    <label for="spec7">Pathologist</label>
    <input type="radio" name="specialty" id="spec8" value="Cytotech">
    <label for="spec8">Cytotech</label>
    <input type="radio" name="specialty" id="spec9" value="Other">
    <label for="spec9">Other</label>
  </div>
  <div class="fc-element">
    <label>Message <span>*</span></label>
    <textarea type="text" name="description" required="" placeholder="To protect patient privacy please do not include any identifying information about the patient or caregiver"></textarea>
  </div>
  <!--<div class="fc-element" >
<div class="g-recaptcha" data-sitekey="6LdWhgQoAAAAAA7SVHl0HoL9MADNodjkBcWvBZyP"></div>
<div id="captcha" style="font-size:13px;color:red;margin-top:12px;"></div>
</div>-->
  <div id="alert"></div>
  <!--<button type="submit" class="g-recaptcha" 
        data-sitekey="6LcmHgMpAAAAANHBE4P7XtRGABiunOqyNIYg0zYM" 
        data-callback='onSubmit' 
        data-action='submit'>Contact us ></button>-->
  <button type="submit">Contact us &gt;</button>
</form>

Text Content

 * Patient site
 * VERACYTE SITE
 * VERACYTE Portal

 * LATEST NEWS & EVIDENCE
 * Patient/Physician Stories
 * Events
 * Practice Resources
 * Physician Portal
 * Afirma
   GRID

 * Patient site
 * VERACYTE SITE
 * VERACYTE Portal

 * LATEST NEWS & EVIDENCE
 * Patient/Physician Stories
 * Events
 * Practice Resources
 * Physician Portal
 * Afirma
   GRID




NEW RESEARCH PRESENTED AT ENDO 2024

Veracyte recently returned from the 44th annual ENDO meeting in Boston, where we
were able to attend compelling presentations and connect with physicians from
around the world. We were also able to contribute research of our own by
presenting 3 studies during the conference, including the validation of the
Afirma® GRID thyroid tumor invasion & metastases signatures.

 


RETROSPECTIVE ANALYSIS OF MRNA EXPRESSION BASED SIGNATURES OF THYROID TUMOR
INVASION AND METASTASES

--------------------------------------------------------------------------------



--------------------------------------------------------------------------------

By performing whole-transcriptome derived analysis on each thyroid FNA sample
that Veracyte receives, a tremendous amount of data is generated on every
nodule.1 This creates the potential for novel research, such as the two tumor
behavior signatures examined in this study. The first of these signatures is the
invasion signature, which predicts the risk of a tumor lacking clinically
significant vascular or extra-thyroidal invasion. The second signature predicts
the risk of a tumor lacking clinically significant lymph node metastases.

This study evaluated the performance of these two predictive signatures among a
cohort of 203 patients with cytologically indeterminate nodules with Afirma GSC
Suspicious results that ultimately underwent thyroid surgery, 152 of which were
Bethesda III and 51 of which were Bethesda IV.

Ultimately, this study confirmed the ability of these two signatures to rule out
significant tumor features with >95% NPV in over half of the studied cohort.
Specifically, the invasion signature ruled out 57% of the samples with a 99% NPV
and 57% specificity, and the lymph node metastases signature ruled out 55% of
the samples with a 100% NPV and 55% specificity.

View Poster

 


PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) EXPRESSION IN CYTOLOGICALLY
INDETERMINATE AND MALIGNANT THYROID NODULES

--------------------------------------------------------------------------------



--------------------------------------------------------------------------------

Prostate-specific membrane antigen (PSMA), a transmembrane protein encoded by
FOLH1, is a receptor expressed in a variety of solid tumors. This study aimed to
characterize PSMA expression in a large cohort of thyroid nodules. FOLH1 (PSMA)
mRNA expression was analyzed across 47,695 thyroid nodules
sent for Afirma Genomic Sequencing Classifier (GSC) molecular testing.

Here’s what this study found:

 * PSMA expression was found to be higher among GSC Suspicious and BV/VI nodules
   than GSC Benign nodules
 * Samples with PAX8-PPARG, ALK/RET fusions had higher PSMA expression than GSC
   Benign
 * Samples with TSHR variants had the lowest PSMA expression in both GSC
   Suspicious and Bethesda V/VI samples

This study demonstrates PSMA expression may provide further thyroid tumor
prognostic information, though the basis for increased PSMA expression in the
setting of PPARG and other fusions is an opportunity for future investigation,
as are the roles of preoperative assessment of PSMA expression and PSMA-based
imaging and therapy in the setting of advanced thyroid cancer.

View Poster

 


CANCER-ASSOCIATED FIBROBLASTS CORRELATE WITH AGGRESSIVE THYROID CANCER BEHAVIOR:
INSIGHTS FROM FOUR LARGE PATIENT COHORTS

(Oral Presentation)

Recently, immune signatures that included the detection of cancer-associated
fibroblasts have been identified as a predictor of aggressive thyroid cancer.²
These fibroblasts have yet to be analyzed in thyroid tumor FNA samples, however.
In this study, associations between CAF gene signatures and tumor
characteristics were explored across 4 large cohorts:

 * A 47,695 sample Afirma GSC cohort
 * A 318 sample retrospective FNA cohort from Memorial Health System with
   pathology outcome
   data
 * A cohort of 496 papillary thyroid cancers from TCGA
 * A 312 sample resection cohort from Vanderbilt University Medical
   Center-University of Washington

In this study, a novel thyroid-cancer specific CAF gene signature was created
and the ability to detect a thyroid-cancer specific CAF gene signature in
thyroid FNAs was demonstrated across these cohorts. In addition, certain CAF
subsets demonstrated prognostic potential: specifically, SFRP2+ CAFs were found
to be associated with aggressive characteristics such as shorter
progression-free survival, tumor invasion,
and lymph node metastases.

 

CONCLUSION

We’re happy that Veracyte could take part in the research presented at ENDO, and
we feel that this research serves as a great example of what’s possible with
Afirma® GRID. If you have questions about the Afirma GRID platform or are
interested in collaborating with us, fill out the form below.

REFERENCES:

 1. https://www.illumina.com/content/dam/illumina-marketing/documents/products/datasheets/datasheet-truseq-rna-access.pdf
 2. GJ Xu, et al, Cell Genom, 2023.

BACK <
First name *
Last name *
Email *
Institution *
Zip code *
Which tests interest you (select all that apply) *
Afirma Genomic Sequencing Classifier Afirma Xpression Atlas
More about you *
Endocrinologist Endocrine surgeon Head and neck surgeon General surgeon Surgeon
Radiologist Pathologist Cytotech Other
Message *

Contact us >
How can we help?
Veracyte representatives are happy to assist you and discuss how to integrate
our tests into your practice.



HEADQUARTERS

6000 Shoreline Court, Suite 300

South San Francisco, CA 94080


CLIENT SERVICES

Monday-Friday, 5:30AM – 5PM (Pacific Time)

+1.844.464.5864 Office

+1.650.243.6388 Fax


SUPPORT EMAIL

support@veracyte.com

References: 1. Data on file. 2. Hu M, et al, JCEM, 2021. 3. Patel KN, et al,
JAMA Surg, 2018. 4. Ali SZ, et al, Cancer Cytopathol, 2019. 5. Hao Y, et al, BMC
Syst Biol, 2019. 6. Angell TE, et al, Thyroid, 2019. 7. San Martin VT, et al,
JCEM 2019. 8. Andrioli M, et al, Endocr Pathol, 2020. 9. Wei S, et al, Cancer
Cytopathol, 2019. 10. Harrell RM, et al, Endocr Pract, 2018. 11. Endo M, et al,
Thyroid, 2019. 12. Goldner W, et al, Thyroid, 2019. 13. Stack, et al, ATA, 2019.
14. TCGA Research Network, Cell, 2014. 15. Yoo SK, et al, PLOS Genet, 2016. 16.
Nasr C, et al, JCEM, 2022. 17. Whitmer D, et al, Frontiers in Endo, 2023. 18.
Randolph G, et al, Thyroid, 2022. 19. Polavarapu P, et al, Journal of Endo Soc,
2021. 20. Melilo RM, et al, JCEM, 2012. 21. Cibas ES, et al, Ann Intern Med,
2013. 22. Cibas ES, et al, Thyroid 2017. 23.
illumina.com/content/dam/illumina-marketing/documents/products/datasheets/datasheet-truseq-rna-access.pdf


CONTACT US TODAY

Call 1.888.923.4762 or email support@veracyte.com

TERMS & CONDITIONS

PRIVACY POLICY

Afirma is available as part of Veracyte’s CLIA-validated laboratory developed
test (LDT) service. This test has not been cleared or approved by the FDA.

© 2023 Veracyte, Inc. All rights reserved. Afirma, Veracyte, the Afirma logo,
and the Veracyte logo are registered trademarks of Veracyte.



This website uses cookies to measure and analyze website performance and usage,
enhance user experiences, personalize content and ads, and provide social media
and other third party features. By clicking "Accept All Cookies", you are
directing Veracyte to disclose information that may be considered personal
information to third parties for these purposes. You may click the "Reject All"
button to reject all cookies except those that are necessary for the website to
function and cannot be switched off in our system. You may also Additional
information about the cookies this website uses is available in our Cookies
Settings.
Cookies Settings Reject All Accept All Cookies



COOKIE PREFERENCE CENTER

When you visit our website, we store cookies on your browser to collect
information which is used to measure and analyze website performance and usage,
enhance user experiences, personalize content and ads, and provide social media
and other third-party features. You can choose to opt out of all third-party
cookies on our website, other than those that are “necessary”, by turning off
the category below; however, this may impact the functionality of the website.
Click on the different category headings to find out more and to change
settings.
Allow All


MANAGE CONSENT PREFERENCES

STRICTLY NECESSARY COOKIES

Always Active

These cookies are necessary for our website to function properly and cannot be
switched off in our systems. Without these cookies, we cannot respond to your
requests or provide you with the services you request or access on our website.
For example, we use these cookies to do the following: to remember information
you have entered on forms during a web browser session; for security purposes;
and to route users to specific applications or specific servers. You can set
your browser to block or alert you about these cookies, but if you do so, some
parts of our website will not function properly.

Cookies Details‎

PERFORMANCE COOKIES

Performance Cookies

These cookies collect information about how you use our website - e.g. which
pages you visit and if you experience any errors. They allow us to count visits
and traffic sources so we can measure and improve the performance of our
website. For example, they help us to know which pages are the most and least
popular and see how visitors move around the site. Some of our performance
cookies are managed for us by third parties. If you do not allow these cookies
we will not know when you have visited our site and will not be able to monitor
its performance. Where required by law, we will obtain your consent before
placing these cookies.

Cookies Details‎
Back Button


COOKIE LIST



Search Icon
Filter Icon

Clear
checkbox label label
Apply Cancel
Consent Leg.Interest
checkbox label label
checkbox label label
checkbox label label

Reject All Confirm My Choices